| MAGE-A3 regulates tumor stemness in gastric cancer through the PI3K/AKT pathway. | MAGE-A3 regulates tumor stemness in gastric cancer through the PI3K/AKT pathway.
Yu QY, Wang ZW, Zhou MY, Li SF, Liao XH., Free PMC Article | 12/31/2022 |
| MAGEA3 serves as an independent indicator for predicting the prognosis of ESCC. | MAGEA3 serves as an independent indicator for predicting the prognosis of ESCC.
Liu S, Chen H, Ge X, Gao Z, Shi Y, Yang M. | 03/19/2022 |
| Re-examination of MAGE-A3 as a T-cell Therapeutic Target. | Re-examination of MAGE-A3 as a T-cell Therapeutic Target.
Martin AD, Wang X, Sandberg ML, Negri KR, Wu ML, Toledo Warshaviak D, Gabrelow GB, McElvain ME, Lee B, Daris ME, Xu H, Kamb A., Free PMC Article | 01/15/2022 |
| Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. | Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma.
Craig AJ, Garcia-Lezana T, Ruiz de Galarreta M, Villacorta-Martin C, Kozlova EG, Martins-Filho SN, von Felden J, Ahsen ME, Bresnahan E, Hernandez-Meza G, Labgaa I, D'Avola D, Schwartz M, Llovet JM, Sia D, Thung S, Losic B, Lujambio A, Villanueva A., Free PMC Article | 10/30/2021 |
| IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis. | IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis.
Haase J, Misiak D, Bauer M, Pazaitis N, Braun J, Pötschke R, Mensch A, Bell JL, Dralle H, Siebolts U, Wickenhauser C, Lorenz K, Hüttelmaier S., Free PMC Article | 10/30/2021 |
| Immunological and functional aspects of MAGEA3 cancer/testis antigen. | Immunological and functional aspects of MAGEA3 cancer/testis antigen.
Das B, Senapati S. | 09/4/2021 |
| Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer. | Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer.
Khalvandi A, Abolhasani M, Madjd Z, Shekarabi M, Kourosh-Arami M, Mohsenzadegan M. | 05/15/2021 |
| LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma progression by regulating MAGEA3 and DCAF4L2 expression. | LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma progression by regulating MAGEA3 and DCAF4L2 expression.
Zhang X, Xu S, Hu C, Fang K, Zhou J, Guo Z, Zhu G, Li L. | 03/28/2021 |
| MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation. | MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation.
Chen A, Santana AL, Doudican N, Roudiani N, Laursen K, Therrien JP, Lee J, Felsen D, Carucci JA., Free PMC Article | 12/26/2020 |
| Aberrantly enhanced melanoma-associated antigen (MAGE)-A3 expression facilitates cervical cancer cell proliferation and metastasis via actuating Wnt signaling pathway. | Aberrantly enhanced melanoma-associated antigen (MAGE)-A3 expression facilitates cervical cancer cell proliferation and metastasis via actuating Wnt signaling pathway.
Gao X, Chen G, Cai H, Wang X, Song K, Liu L, Qiu T, He Y. | 10/3/2020 |
| Data indicate that miR-1273g represses melanoma antigen family A 3/melanoma antigen family A 6 (MAGEA3/6 )expression in colorectal cancer (CRC) cells and tissues, which may suggest a cancer-specific therapeutic. | miR-1273g silences MAGEA3/6 to inhibit human colorectal cancer cell growth via activation of AMPK signaling.
Wu F, Liu F, Dong L, Yang H, He X, Li L, Zhao L, Jin S, Li G. | 09/28/2019 |
| GPC3, MAGE1 and 3 were increased with advanced tumor stage, size, and nodule numbers in Hepatocellular Carcinoma | Glypican-3 and Melanoma Antigen Genes 1 and 3 as Tumor Markers for Hepatocellular Carcinoma.
El-Wahab NM, Rashed HG, El-Sherif WT, Sayed SK, Abd-Elmalek MO, Refaiy A, Fakhry H, Mokhtar AA. | 04/27/2019 |
| Study reports that MAGEA3 interacts with STAT1 and regulates the expression of tyrosine phosphorylated STAT1 (pY-STAT1) in tumor cells. MAGEA3 expression in tumor cells is associated with immune cells infiltration into tumor microenvironment and anti-tumor immune responses. | Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment.
Wang Y, Song X, Zheng Y, Liu Z, Li Y, Qian X, Pang X, Zhang Y, Yin Y., Free PMC Article | 04/20/2019 |
| MAGEA3 and CTAG1B are expressed in urothelial bladder neoplasms and may be useful in prognosis | Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer.
Lausenmeyer EM, Braun K, Breyer J, Gierth M, Denzinger S, Burger M, Voelker HU, Otto W. | 03/30/2019 |
| High MAGEA3 expression is associated with Transitional Cell Carcinoma of Bladder. | Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder.
Afsharpad M, Nowroozi MR, Mobasheri MB, Ayati M, Nekoohesh L, Saffari M, Zendehdel K, Modarressi MH. | 03/2/2019 |
| rapid drop (>50%) in blood level within 4 weeks of melanoma treatment associated with long-term response to therapy | Quantitative changes of melanoma-associated antigens as a biomarker for targeted therapy response.
Arenberger P, Fialova A, Gkalpakiotis S, Pavlikova A, Arenbergerova M. | 03/3/2018 |
| the objective response rate was lower in this study than in other studies carried out in the same setting with the MAGE-A3 immunotherapeutic. Investigation of a gene signatures (GS) to predict clinical benefit to adjuvant MAGE-A3 immunotherapeutic treatment is ongoing in another melanoma study. | Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P., Free PMC Article | 12/23/2017 |
| Administering autologous CD4(+) T cells that are genetically engineered to express an MHC class II-restricted antitumor TCR that targets MAGE-A3 can be used safely in the treatment of metastatic neoplasms. | Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA., Free PMC Article | 10/28/2017 |
| Data show that overall survival (OS) was significantly lower for patients expressing pan-MAGE or MAGE-A1/A3/A4 in both independent cohorts. | MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.
Laban S, Giebel G, Klümper N, Schröck A, Doescher J, Spagnoli G, Thierauf J, Theodoraki MN, Remark R, Gnjatic S, Krupar R, Sikora AG, Litjens G, Grabe N, Kristiansen G, Bootz F, Schuler PJ, Brunner C, Brägelmann J, Hoffmann TK, Perner S., Free PMC Article | 08/19/2017 |
| These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible. | Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK, Wang Y, Sundaram K, Bai F, Lucas KG. | 07/29/2017 |
| MAGEA3 may be demethylated in MPNST and plexiform type neurofibroma in NF-1 patients | MAGEA3 methylation status is associated with prognosis of malignant peripheral nerve sheath tumor and with neurofibroma type in neurofibromatosis type 1.
Nobeyama Y, Nakagawa H. | 07/29/2017 |
| MAGEA3 was overexpressed in colorectal cancer tissue compared with healthy colon. MAGEA3 expression positively correlated with colorectal cancer progression. | Expression of Cancer Testis Antigens in Colorectal Cancer: New Prognostic and Therapeutic Implications.
Tarnowski M, Czerewaty M, Deskur A, Safranow K, Marlicz W, Urasińska E, Ratajczak MZ, Starzyńska T., Free PMC Article | 02/25/2017 |
| Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS). | Influence of Photodynamic Therapy on the Expression of Cancer/Testis Antigens in Squamous Cell Carcinoma of the Head and Neck.
Theodoraki MN, Lorenz KJ, Schneider J, Thierauf JC, Spagnoli G, Schuler PJ, Hoffmann TK, Laban S. | 01/28/2017 |
| MAGE-A3 expression is regulated epigenetically by promoter methylation, and that its expression contributes to gastric cell proliferation and drug sensitivity. | Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.
Xie C, Subhash VV, Datta A, Liem N, Tan SH, Yeo MS, Tan WL, Koh V, Yan FL, Wong FY, Wong WK, So J, Tan IB, Padmanabhan N, Yap CT, Tan P, Goh LK, Yong WP. | 12/24/2016 |
| Progression free survival and levels of MAGE-A3 expression in non-small cell lung carcinoma patients with the three modes of acquired resistance are negatively correlated. | Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
Jin J, Liu BZ, Wu ZM. | 09/17/2016 |